Wedbush downgraded Iveric bio to Neutral from Outperform with a price target of $40, up from $35, after the company entered into a definitive agreement under which Astellas Pharma will acquire 100% of its outstanding shares for $40 per share in cash for a total equity value of $5.9B.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE: